Results 11 to 20 of about 5,828,957 (159)

Finasteride Side Effects and Post-Finasteride Syndrome in Male Androgenic Alopecia [PDF]

Journal of Mind and Medical Sciences, 2015
Finasteride is in present a relatively frequent prescribed drug for male androgenic alopecia. The adverse effects reported by some patients seem to be notable, consisting of various (physical, mental/ neurological, sexual, etc.) manifestations which are ...
Manea Mirela, Paunica Ioana, Puiu Gabriela Maria, Manea Costin Mihnea   +3 more
doaj   +3 more sources

Finasteride withdrawal induces anxiety-like behavior and novelty avoidance in adult male rats. [PDF]

J Neuroendocrinol
Abstract Finasteride, an inhibitor of the enzyme 5alpha‐reductase, prescribed for benign prostatic hyperplasia and androgenetic alopecia, induces a wide variety of side effects during treatment and upon withdrawal, like sexual dysfunction and cognitive and psychological disorders, inducing the so‐called post‐finasteride syndrome (PFS).
Cioffi L, Diviccaro S, Chrostek G, Severino FPU, Giatti S, Scheggia D, Melcangi RC.   +6 more
europepmc   +2 more sources

Post-Finasteride Syndrome: An Induced Delusional Disorder with the Potential of a Mass Psychogenic Illness? [PDF]

Skin Appendage Disord, 2019
Post-finasteride syndrome (PFS) has been claimed to occur in men who have taken oral finasteride to treat either hair loss or benign prostatic hyperplasia, independent of age, dosage, or indication. By definition, the condition is characterized by sexual dysfunction, somatic symptoms, and psychological disorders that persist after cessation of ...
Trüeb RM, Régnier A, Dutra Rezende H, Gavazzoni Dias MFR.   +3 more
europepmc   +4 more sources

Emotional Consequences of Finasteride: Fool’s Gold

American Journal of Men's Health, 2018
Androgenetic alopecia, the gradual, progressive loss of hair frequently results in psychological despair, in part related to changes in self-image. Current androgenetic alopecia treatments are limited to hair transplantation and medications that inhibit ...
Christine Anne Ganzer PhD, Alan Roy Jacobs MD   +1 more
doaj   +2 more sources

5α-Reductase Isoenzymes: From Neurosteroid Biosynthesis to Neuropsychiatric Outcomes [PDF]

NeuroSci
5a-reductase (5a-R) isozymes are essential for androgen metabolism and neurosteroid biosynthesis, linking endocrinology and neuropsychiatry. This systematic review, conducted in accordance with PRISMA 2020 guidelines, aimed to synthesize current evidence
Carmen Rodriguez-Cerdeira
doaj   +2 more sources

8679 Case: The Sexual, Physical and Psychological Effects of Post-Finasteride Syndrome [PDF]

J Endocr Soc
Abstract Disclosure: E.M. Lonergan: None. S.M. Maher: None. I. Yaseen: None. D.B. O'Shea: None. Post-finasteride syndrome (PFS) is an increasingly recognised disorder with a myriad of physical and neuropsychiatric symptoms persisting for greater than three months in a small proportion of patients treated with Finasteride ...
Lonergan, Eibhlin Marie, Maher, Sean Martin, Yaseen, Ibrahim, O'Shea, Donal Brendan   +3 more
europepmc   +2 more sources

Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System. [PDF]

Int J Dermatol
ABSTRACT Background The United States Food and Drug Administration (FDA) approved oral finasteride for androgenetic alopecia. In 2022, approximately 2.6 million U.S. men used it for hair loss and prostate conditions. Post‐finasteride syndrome (PFS), proposed in 2012, involves persistent sexual and neuropsychiatric adverse events (AEs) after cessation ...
Gupta AK, Talukder M, Keene SA, Bamimore MA.   +3 more
europepmc   +2 more sources

Exploration of the Possible Relationships Between Gut and Hypothalamic Inflammation and Allopregnanolone: Preclinical Findings in a Post-Finasteride Rat Model [PDF]

Biomolecules
Background: Finasteride, a 5α-reductase inhibitor commonly prescribed for androgenetic alopecia, has been linked to persistent adverse effects after discontinuation, known as post-finasteride syndrome (PFS).
Silvia Diviccaro, Roberto Oleari, Federica Amoruso, Fabrizio Fontana, Lucia Cioffi, Gabriela Chrostek, Vera Abenante, Jacopo Troisi, Anna Cariboni, Silvia Giatti, Roberto Cosimo Melcangi   +10 more
doaj   +2 more sources

Efficacy of Hair Mesotherapy With Biomimetic Peptides and Micronutrients in Patients With Androgenetic Alopecia: A Retrospective Observational Study [PDF]

J Cosmet Dermatol
ABSTRACT Background Hair mesotherapy is increasingly used in the management of androgenetic alopecia (AGA), yet standardized treatment protocols and controlled clinical data are limited. Aims This study aimed to evaluate the efficacy and safety of a mesotherapy formulation containing biomimetic peptides, vitamins, and micronutrients in patients with ...
Köse Ö, Borlu M.
europepmc   +2 more sources

A Scoping Review of Non-Opioid Therapeutics for Opioid Withdrawal: Translational Relevance to Neonatal Opioid Withdrawal Syndrome (NOWS) Research. [PDF]

Clin Transl Sci
ABSTRACT In the wake of the ongoing opioid epidemic, the incidence of neonatal opioid withdrawal syndrome (NOWS) has surged. While the short‐term effects of NOWS are well‐characterized, long‐term physiological and molecular consequences remain unclear.
Mills-Huffnagle SL, Lowden OM, Sullivan RE, McFadden TE, Nyland JE.   +4 more
europepmc   +2 more sources